Same-day Dilapan-S With Adjunctive Misoprostol

Not Applicable

Terminated

Conditions: Therapeutic Abortion

Interventions: Drug: Misoprostol
Drug: Folic Acid

Registration Number: NCT01818414

Lead Sponsor: University of Pittsburgh

Brief Summary: Cervical preparation before second trimester dilation and evacuation (D\&E) reduces risks and complications. Osmotic cervical dilators as well as prostaglandin analogues have been studied for cervical preparation. However, the optimal method for cervical preparation, especially for D\&E procedures that occur on the same day as cervical preparation, is not known. This study will investigate misoprostol versus placebo as an adjunct to Dilapan-S for cervical preparation for same-day D\&E between 16+0 and 20+6 weeks gestation.

HYPOTHESIS: Administration of 400 µg buccal misoprostol compared to placebo at least 3 hours prior to D\&E as an adjunct to cervical preparation with Dilapan-S will decrease operative time for same-day D\&E performed between 16+0 and 20+6 weeks.

Detailed Description: Dilation and evacuation (D\&E) is commonly performed for second trimester abortions and management of second trimester intrauterine fetal demise (IUFD). Cervical preparation prior to second trimester D\&E increases safety.

Osmotic cervical dilators and prostaglandin analogs are used widely for cervical preparation before second trimester D\&E. Osmotic dilators are placed into the cervical canal, radially expand as they absorb moisture and decrease the risk of cervical injury during D\&E. Laminaria tents are the most commonly used osmotic dilator for D\&E cervical preparation but require N18 h to reach maximum diameter. Dilapan-S®, a synthetic osmotic cervical dilator, has a significant dilation effect 2 h after placement with the majority of expansion occurring in 4-6 h according to the manufacturer.

Misoprostol is the most commonly used pharmacologic cervical preparation for D\&E with duration of action between 2 and 4 h after administration. Multiple studies demonstrate the safety of misoprostol before early second trimester abortion. One prospective and four retrospective studies suggest that same-day cervical preparation with Dilapan-S and/or misoprostol for second trimester D\&E through 20 weeks is safe and effective. Misoprostol may be less effective when used alone compared to overnight osmotic dilators for cervical preparation later in the second trimester but has adjunctive benefit on cervical dilation and procedure time when used with overnight osmotic dilators between 16 and 24 weeks. The effect appears most pronounced at N19 weeks gestation. No prospective studies have been published examining misoprostol as an adjunct to osmotic dilators for cervical preparation for same-day D\&E.

Administration of adjunctive misoprostol with Dilapan-S has the potential to effectively prepare the cervix and decrease operative time for same-day D\&E. We compared cervical preparation with Dilapan-S with and without adjunctive buccal misoprostol for same-day D\&E between 16 0/7 and 20 6/7 weeks gestation.

Recruitment & Eligibility

Status: TERMINATED

Sex: Female

Target Recruitment: 29

Inclusion Criteria

Age greater than or equal to 18 years (no upper age limit)
Gestational age between 16+0 and 20+6 weeks gestation on day of D&E with confirmation of gestational age by ultrasound
Desires D&E for termination of pregnancy or for fetal demise
Able to provide written informed consent
Able to comply with study procedures
English-speaking

Exclusion Criteria

Known allergy or contraindication to misoprostol
Pregnancy with a multiple gestation
Known bleeding disorder or current anticoagulation therapy (within one month of procedure)
Active bleeding or hemodynamically unstable at enrollment
Signs of chorioamnionitis or clinical infection at enrollment
Signs of spontaneous labor or cervical insufficiency at enrollment

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Misoprostol	Misoprostol	Misoprostol 400 mcg buccal 3 hours prior to D\&E as an adjunct to same-day Dilapan-S.
Folic Acid	Folic Acid	Folic acid 4 mg buccally 3 hours prior to D\&E as an adjunct to same-day Dilapan-S

Primary Outcome Measures

Name	Time	Method
Operative Time	Day 1 of the study	The primary outcome will be operative time. Operative time will be measured from initial passage of an instrument into the uterus to start the D\&E. The end of operative time will be measured by the removal of the last instrument from the uterus to complete the D\&E.

Secondary Outcome Measures

Name	Time	Method
Patient Pain	Day 1	Change in pain from baseline to immediately preoperatively using a 100-mm Visual Analogue Scale ("100-mm Visual Analogue Scale with 0 indicating "no pain" and 100 indicating "worst pain in my life")
Number of Participants With Postoperative Satisfaction	Day 1	Patient postoperative satisfaction with cervical preparation method
Complications	Day 1	Incidence of surgical complications related to D\&E
Number of Providers With Overall Satisfaction	Day 1	Provider overall satisfaction with cervical preparation

Trial Locations

Locations (2): Planned Parenthood of Western Pennsylvania
🇺🇸
Pittsburgh, Pennsylvania, United States
Univeristy of Pittsburgh, Magee-Womens Hospital of UPMC
🇺🇸
Pittsburgh, Pennsylvania, United States